Vesilute vs DSIP
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.
- DSIP is an endogenous neuropeptide originally isolated from rabbit cerebrospinal fluid that induces delta-wave (deep) sleep. It also modulates stress response, cortisol regulation, and LH secretion, making it valuable for sleep optimization and stress management.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~30–60 minutes; however downstream sleep effects last 4–6 hours
- Admin Route
- SubQ, Oral
- SubQ, IV, Intranasal
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 100–400 mcg
- Frequency
- Daily for 10–30 days
- Once nightly
- Key Benefits
- Supports retinal photoreceptor cell function and survival
- May slow progression of age-related macular degeneration
- Reduces retinal cell apoptosis from oxidative stress and aging
- Anti-aging effects on retinal pigment epithelium
- Potential support in diabetic retinopathy management
- Preserves visual acuity with aging
- Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols
- Induces and deepens delta-wave (slow-wave) sleep
- Reduces cortisol and normalizes HPA axis
- Improves sleep quality in insomnia patients
- Anti-stress and anxiolytic effects
- May improve opiate/alcohol withdrawal symptoms
- Analgesic properties through opioid modulation
- Antioxidant and neuroprotective effects
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant ocular adverse events reported at standard doses
- Generally well tolerated
- Mild grogginess next morning at higher doses
- Rare: hypotension
- Potential for altered dream patterns
- Stacks With
- —
- —